Canaccord Genuity Maintains a 'Buy' on AVEO Pharmaceuticals (AVEO); 2012 A Critical Year
Tweet
Share
E-mailGet Alerts AVEO Hot Sheet
Price: $15.00 --0%
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Rating Summary:
4 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 5 | New: 25
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on AVEO Pharmaceuticals (NASDAQ: AVEO) price target of $28.00.
Canaccord analyst says, "We see 2012 as a critical year for the company given major randomized clinical trial readouts and potential NDA filing of lead drug, tivozanib."
"Key drivers: Tivozanib in renal cell carcinoma and ficlatuzumab in non-small cell lung cancer...Phase III top-line results from TIVO-1 evaluating tivozanib as treatment for renal cell carcinoma... Management reiterated that all of the TIVO-1 events required for unblinding the trial should occur in Q4/11 at the earliest. We expect top-line data in Q1/12...Randomized Phase II data from a non-small cell lung cancer trial evaluating ficlatuzumab...Ficlatuzumab production arrangements for Phase III will be finalized later this year following further analysis of the open-label Phase II."
For more ratings news on AVEO Pharmaceuticals click here and for the rating history of AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $16.51 yesterday.
Canaccord analyst says, "We see 2012 as a critical year for the company given major randomized clinical trial readouts and potential NDA filing of lead drug, tivozanib."
"Key drivers: Tivozanib in renal cell carcinoma and ficlatuzumab in non-small cell lung cancer...Phase III top-line results from TIVO-1 evaluating tivozanib as treatment for renal cell carcinoma... Management reiterated that all of the TIVO-1 events required for unblinding the trial should occur in Q4/11 at the earliest. We expect top-line data in Q1/12...Randomized Phase II data from a non-small cell lung cancer trial evaluating ficlatuzumab...Ficlatuzumab production arrangements for Phase III will be finalized later this year following further analysis of the open-label Phase II."
For more ratings news on AVEO Pharmaceuticals click here and for the rating history of AVEO Pharmaceuticals click here.
Shares of AVEO Pharmaceuticals closed at $16.51 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lowe's (LOW) PT Lowered to $275 at Guggenheim
- Wells Fargo Upgrades Portland General Electric Company (POR) to Overweight
- BofA Securities Starts Mobility Global (MBGL) at Neutral
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
